HK1202548A1 - -標記的葉酸/抗葉酸劑類似物 - Google Patents

-標記的葉酸/抗葉酸劑類似物

Info

Publication number
HK1202548A1
HK1202548A1 HK15103227.2A HK15103227A HK1202548A1 HK 1202548 A1 HK1202548 A1 HK 1202548A1 HK 15103227 A HK15103227 A HK 15103227A HK 1202548 A1 HK1202548 A1 HK 1202548A1
Authority
HK
Hong Kong
Prior art keywords
antifolate
analogues
folate
labelled
labelled folate
Prior art date
Application number
HK15103227.2A
Other languages
English (en)
Inventor
．施布利
．莫澤
．穆勒
．艾梅塔美
．貝特澤爾
．格羅恩
Original Assignee
Merck & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Cie filed Critical Merck & Cie
Publication of HK1202548A1 publication Critical patent/HK1202548A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15103227.2A 2012-05-08 2015-03-31 -標記的葉酸/抗葉酸劑類似物 HK1202548A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167126 2012-05-08
PCT/EP2013/059584 WO2013167653A1 (en) 2012-05-08 2013-05-08 18f-labelled folate/antifolate analogues

Publications (1)

Publication Number Publication Date
HK1202548A1 true HK1202548A1 (zh) 2015-10-02

Family

ID=48407549

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103227.2A HK1202548A1 (zh) 2012-05-08 2015-03-31 -標記的葉酸/抗葉酸劑類似物

Country Status (18)

Country Link
US (1) US10357576B2 (zh)
EP (1) EP2864329B1 (zh)
JP (1) JP6198814B2 (zh)
KR (1) KR102116000B1 (zh)
CN (1) CN104379585B (zh)
AU (1) AU2013258027B2 (zh)
CA (1) CA2870124C (zh)
DK (1) DK2864329T3 (zh)
EA (1) EA201401225A1 (zh)
ES (1) ES2703627T3 (zh)
HK (1) HK1202548A1 (zh)
IL (1) IL235476B (zh)
PL (1) PL2864329T3 (zh)
PT (1) PT2864329T (zh)
SG (1) SG11201406481TA (zh)
TR (1) TR201819802T4 (zh)
WO (1) WO2013167653A1 (zh)
ZA (1) ZA201407266B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
US12023390B2 (en) * 2017-03-20 2024-07-02 Merck Patent Gmbh Isomerically pure 18F-labelled tetrahydrofolates
EP3671511B1 (en) 2018-12-19 2022-07-06 Rohde & Schwarz GmbH & Co. KG Communication system and method
DE102019110904B4 (de) * 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
JP2023533724A (ja) 2020-07-02 2023-08-04 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2592302C (en) 2004-12-23 2013-10-29 Purdue Research Foundation Positron emission tomography imaging method
JP4503039B2 (ja) 2006-04-27 2010-07-14 三洋電機株式会社 回路装置
EP2109466B1 (en) 2007-02-07 2014-11-12 Purdue Research Foundation Positron emission tomography imaging method
US8344140B2 (en) 2007-04-11 2013-01-01 Merck Eprova Ag 18F-labelled folates
CN107573347A (zh) 2007-04-11 2018-01-12 默克和西伊公司 18f‑标记的叶酸
CN101646672B (zh) 2007-04-11 2015-08-19 默克和西伊公司 用于诊断成像和放射治疗的叶酸轭合物和相应的金属螯合物络合物
CA2670379C (en) 2007-04-11 2015-06-23 Merck Eprova Ag 18f-labelled folates
US20110286921A1 (en) 2008-10-10 2011-11-24 Merck & Cie 18f-labelled folates as pet radiotracers

Also Published As

Publication number Publication date
US10357576B2 (en) 2019-07-23
TR201819802T4 (tr) 2019-01-21
EA201401225A1 (ru) 2015-04-30
CA2870124A1 (en) 2013-11-14
EP2864329B1 (en) 2018-09-26
IL235476A0 (en) 2014-12-31
AU2013258027A1 (en) 2014-11-13
KR20150010970A (ko) 2015-01-29
ES2703627T3 (es) 2019-03-11
JP6198814B2 (ja) 2017-09-20
KR102116000B1 (ko) 2020-05-29
CA2870124C (en) 2021-02-16
PL2864329T3 (pl) 2019-03-29
AU2013258027B2 (en) 2017-11-30
JP2015516405A (ja) 2015-06-11
PT2864329T (pt) 2019-01-10
CN104379585B (zh) 2018-07-06
DK2864329T3 (en) 2019-01-21
US20150125390A1 (en) 2015-05-07
SG11201406481TA (en) 2014-11-27
EP2864329A1 (en) 2015-04-29
CN104379585A (zh) 2015-02-25
WO2013167653A1 (en) 2013-11-14
IL235476B (en) 2019-09-26
ZA201407266B (en) 2016-09-28

Similar Documents

Publication Publication Date Title
ZA201702364B (en) Glucagon analogues
HK1206757A1 (zh) 胰高血糖素類似物
HK1202548A1 (zh) -標記的葉酸/抗葉酸劑類似物
PL3181128T3 (pl) Kompozycja farmaceutyczna nilotynibu
EP2821033A4 (en) PARTLY DOUBLE-STRUCTURED STENT WITH PROJECTION FUNCTION
HK1203943A1 (zh) 喹唑啉二酮衍生物
HK1204931A1 (zh) 胃飢餓素衍生物
GB201903206D0 (en) n
PL2873355T3 (pl) Komponent podstawowy
GB201221388D0 (en) GPS Doll
HK1206745A1 (zh) 類似物
RS55467B1 (sr) Stent
EP2865680A4 (en) XANTHINE DERIVATIVE
EP2922817A4 (en) OMEGA-3 ANALOGUES
PL2732798T3 (pl) Stent tymczasowy
GB2508797B (en) Self contained staircase
GB201218696D0 (en) Standing aid
GB201314742D0 (en) Siv ball
AU342207S (en) Jewelley setting
GB201221028D0 (en) Cushion
GB201210169D0 (en) Seating
AU343979S (en) Stool
GB201214689D0 (en) Foldable blank
GB201214302D0 (en) Seats
GB201206002D0 (en) Inserter